Cytokeratin 14/16 (S5) polyclonal antibody

P02533/P08779

In Bowen's disease, the characteristic malignancy of the epidermis exhibits distinct expression patterns of Cytokeratin 14. Mutations in the gene encoding human Cytokeratin 14 lead to epidermolysis bullosa simplex, an inheritied skin disorder characterized by skin blistering due to basal keratinocyte fragility.Cytokeratin 16 is expressed in benign stratified squamous epithelium and squamous cell carcinoma of the head and neck, as well as luminal cells of mammary gland and sweat ducts. It is absent in noninvasive breast carcinomas and normal breast tissue. Mutations in the Cytokeratin 16 gene cause various diseases, including pachyonychia congenita type 1 (PC1), nonepidermolytic palmoplantar keratoderma (NEPPK) and unilateral palmoplantar verrucous nevus (UPVN).

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).

Cytokeratin 14/16 (S5) pAb detects endogenous levels of Cytokeratin 14 and Cytokeratin 16 protein.

Immunohistochemistry (IHC) analyzes of Cytokeratin 14/16 (S5) pAb in paraffin-embedded human breast carcinoma tissue.

For research use only, not for use in diagnostic procedure.

Synthetic peptide, corresponding to the N-terminus of Human Cytokeratin 14